A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Small Cell Lung Cancer (SCLC) · SCLC, Extensive Stage

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin Municipality, China
Contact: Study coordinator (Ningbo Liu, Doctor) · liuningbo@tjmuch.com · +8615602036608

Study leads

Dingzhi Huang, Doctor
Principal Investigator
Tianjin Medical University Cancer Institute and Hospital
Ningbo Liu, Doctor
Principal Investigator
Tianjin Medical University Cancer Institute and Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Lung Cancer Registry

Lung Cancer · NSCLC Stage IV · NSCLC, Stage III

Abroad (travel likely)Recruiting

Salzburg, Austria · Innsbruck, Austria

Cognitive Screening in Lung Cancer Patients

Lung Disease · NSCLC (Non-small Cell Lung Cancer) · SCLC

Abroad (travel likely)Recruiting

Milan, Italy

Pulmonary Rehabilitation in Advanced Lung Cancer Survivors

Non-small Cell Lung Cancer Stage III · Non-small Cell Lung Cancer Stage IV · Non-small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Cleveland, United States

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Cancer · Breast Cancer · Non-Small Cell Lung Cancer (NSCLC)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beijing, China